[{"id":"3aa290d8-6797-4cf2-a109-40a5ce47ce82","acronym":"NCI-2021-04325","url":"https://clinicaltrials.gov/study/NCT04940299","created_at":"2021-06-25T22:54:16.715Z","updated_at":"2024-07-02T16:35:03.655Z","phase":"Phase 2","brief_title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","source_id_and_acronym":"NCT04940299 - NCI-2021-04325","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-15"},{"id":"d448b93f-39b9-4496-9d25-48f1c9adcfa3","acronym":"Balise","url":"https://clinicaltrials.gov/study/NCT01897480","created_at":"2021-01-18T08:31:57.339Z","updated_at":"2024-07-02T16:35:16.757Z","phase":"Phase 2","brief_title":"A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","source_id_and_acronym":"NCT01897480 - Balise","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • emibetuzumab (LY2875358)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 08/28/2013","start_date":" 08/28/2013","primary_txt":" Primary completion: 03/14/2016","primary_completion_date":" 03/14/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-01"},{"id":"f55d50ad-dce3-4943-848c-50d3f8bc845d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05536505","created_at":"2022-09-13T12:56:52.478Z","updated_at":"2024-07-02T16:36:03.964Z","phase":"Phase 2","brief_title":"Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC","source_id_and_acronym":"NCT05536505","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2022-09-14"},{"id":"79f05a1d-c2bb-4e73-85ba-8bb2974c7f1e","acronym":"LiquidLung-A","url":"https://clinicaltrials.gov/study/NCT02629523","created_at":"2021-01-18T12:47:07.810Z","updated_at":"2024-07-02T16:36:27.058Z","phase":"Phase 2","brief_title":"Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA","source_id_and_acronym":"NCT02629523 - LiquidLung-A","lead_sponsor":"Chonnam National University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 05/11/2020","study_completion_date":" 05/11/2020","last_update_posted":"2021-08-03"},{"id":"c5c3f118-9c03-4425-9f17-6077a7ad61b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03058094","created_at":"2021-01-18T15:03:44.024Z","updated_at":"2024-07-02T16:37:03.231Z","phase":"Phase 3","brief_title":"A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI","source_id_and_acronym":"NCT03058094","lead_sponsor":"Hangzhou ACEA Pharmaceutical Research Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Fujovee (abivertinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-02-04"},{"id":"597c38b8-7e98-470d-aa9c-96c2aa34b69a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00577707","created_at":"2021-01-18T02:06:49.792Z","updated_at":"2024-07-02T16:37:14.967Z","phase":"Phase 2","brief_title":"Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)","source_id_and_acronym":"NCT00577707","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR exon 19 deletion + EGFR L861Q","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR exon 19 deletion + EGFR L861Q"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2018-01-10"}]